Patients
Physicians
Sponsors
Oncologists
About Us
News
ENG
Last updated 44 days ago
Share
A Study of (Neo)Adjuvant V940 and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)
1012 patients around the world
Available in
Chile
Merck Sharp & Dohme LLC
3
Research sites
1012
Patients around the world
This study is for people with
Skin cancer
Cutaneous Squamous Cell Carcinoma
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Inclusion criteria
Exclusion criteria
Sites
James Lind Centro de Investigación del Cáncer - Temuco
Recruiting
View site
Hochstetter 298, Temuco
James Lind Centro de Investigación del Cáncer - Temuco
Recruiting
View site
Hochstetter 298, Temuco
CIDO SpA-Oncology
Recruiting
View site
Temuco, Araucania, 4810218
CIDO SpA-Oncology
Recruiting
View site
Temuco, Araucania, 4810218
Instituto Oncológico FALP - UIDO
Recruiting
View site
José Manuel Infante 805, Providencia, Región Metropolitana
Instituto Oncológico FALP - UIDO
Recruiting
View site
José Manuel Infante 805, Providencia, Región Metropolitana
See details
Contact us
Contact us
Sponsor
Merck Sharp & Dohme LLC
Conditions
Cutaneous Squamous Cell Carcinoma
Requirements
From 18 Years
All Gender
Unique study ID
clinicaltrials.gov
NCT06295809
About us
Our mission
Our team
Partners
FAQs
Medical news
Latest news
Studies
Interviews
Testimonials
Products
UEPM Onco
UEPM Physicians
Links
Downloads
English
Terms and Conditions
Privacy Policy
Change your consent
English
Terms and Conditions
Privacy Policy
Change your consent
English
Terms and Conditions
Privacy Policy
Change your consent
